Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Targeting BTK through microRNA in chronic lymphocytic leukemia

Arianna Bottoni, Lara Rizzotto, Tzung-Huei Lai, Chaomei Liu, Lisa L. Smith, Rose Mantel, Sean Reiff, Dalia El-Gamal, Karilyn Larkin, Amy J. Johnson, Rosa Lapalombella, Amy Lehman, William Plunkett, John C. Byrd, James S. Blachly, Jennifer A. Woyach, Deepa Sampath

Blood (2016) 128 (26): 3101–3112.

https://doi.org/10.1182/blood-2016-07-727750

Published: 2016

Includes: Supplemental data

Journal Articles

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Kerry A. Rogers, MD, Amy M. Lehman, MAS, Carolyn Cheney, BS, Virginia M. Goettl, DVM , PhD, Rose Mantel, Lisa L. Smith, MS, Minh Tran, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 1259.

https://doi.org/10.1182/blood.V128.22.1259.1259

Published: 2016

Journal Articles

Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

Fabienne McClanahan, MD PhD, Sean D. Reiff, Daphne Guinn, PhD, Minh Tran, Larry Beaver, Samantha McWorther, Rose Mantel, Lisa L. Smith, MS, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 352.

https://doi.org/10.1182/blood.V128.22.352.352

Published: 2016

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Sean D. Reiff, Rose Mantel, Lisa L. Smith, MS, Samantha McWhorter, Virginia M. Goettl, DVM , PhD, Amy J. Johnson, PhD, Sudharsan Eathiraj, Giovanni Abbadessa, MD, Brian Schwartz, MD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 3232.

https://doi.org/10.1182/blood.V128.22.3232.3232

Published: 2016

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

Journal Articles

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Kerry A. Rogers, MD, Dalia El-Gamal, PhD, Harrington K. Bonnie, DVM, Hing A. Zachary, BS, Goettl M. Virginia, DVM, PhD, Mantel Rose, Lisa L. Smith, MS, Lianbo Yu, PhD, Amy J. Johnson, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer A. Woyach, MD

Blood (2015) 126 (23): 2752.

https://doi.org/10.1182/blood.V126.23.2752.2752

Published: 2015

Journal Articles

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Zachary A. Hing, Rose Mantel, Kyle A. Beckwith, Daphne Guinn, Erich Williams, Lisa L. Smith, Katie Williams, Amy J. Johnson, Amy M. Lehman, John C. Byrd, Jennifer A. Woyach, Rosa Lapalombella

Blood (2015) 125 (20): 3128–3132.

https://doi.org/10.1182/blood-2015-01-621391

Published: 2015

Includes: Supplemental data

Journal Articles

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Blood (2014) 123 (12): 1810–1817.

https://doi.org/10.1182/blood-2013-09-527853

Published: 2014

Includes: Supplemental data

Journal Articles

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert, Matthew R. Stefanovski, Virginia M. Goettl, Kelly A. Smucker, Lisa L. Smith, Jason A. Dubovsky, William H. Towns, Jessica MacMurray, Bonnie K. Harrington, Melanie E. Davis, Stefania Gobessi, Luca Laurenti, Betty Y. Chang, Joseph J. Buggy, Dimitar G. Efremov, John C. Byrd, Amy J. Johnson

Blood (2014) 123 (8): 1207–1213.

https://doi.org/10.1182/blood-2013-07-515361

Published: 2014

Includes: Supplemental data

Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Blood (2013) 122 (15): 2539–2549.

https://doi.org/10.1182/blood-2013-06-507947

Published: 2013

Includes: Supplemental data

Journal Articles

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Jennifer A. Woyach, MD, Matthew R Stefanovski, B.S., Virginia Goettl, Amy S. Ruppert, MAS, Kelly A Smucker, Lisa L. Smith, Jason A Dubovsky, Ph.D, William H. Towns, Jessica MacMurray, Melanie E. Davis, Yicheng Mao, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, John C. Byrd, MD, Amy J Johnson, PhD

Blood (2012) 120 (21): 183.

https://doi.org/10.1182/blood.V120.21.183.183

Published: 2012

Journal Articles

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Blood (2012) 120 (21): 775.

https://doi.org/10.1182/blood.V120.21.775.775

Published: 2012

Journal Articles

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

Emilia Mahoney, David M. Lucas, Sneha V. Gupta, Amy J. Wagner, Sarah E. M. Herman, Lisa L. Smith, Yuh-Ying Yeh, Leslie Andritsos, Jeffrey A. Jones, Joseph M. Flynn, Kristie A. Blum, Xiaoli Zhang, Amy Lehman, Hui Kong, Metin Gurcan, Michael R. Grever, Amy J. Johnson, John C. Byrd

Blood (2012) 120 (6): 1262–1273.

https://doi.org/10.1182/blood-2011-12-400184

Published: 2012

Includes: Supplemental data

Journal Articles

Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

Amy J. Johnson, PhD, Lisa L. Smith, Amy J. Wagner, Joshua Hessler, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Xiaoli Zhang, Amy Lehman, David Jarjoura, Michael R. Grever, M.D., Rajat Bannerji, MD, PHD, John C. Byrd, MD

Blood (2010) 116 (21): 971.

https://doi.org/10.1182/blood.V116.21.971.971

Published: 2010

Journal Articles

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway

Blood (2010) 115 (13): 2619–2629.

https://doi.org/10.1182/blood-2009-09-242438

Published: 2010

Includes: Supplemental data

Journal Articles

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Joseph M. Flynn, DO, MPH, FACP, Amy J. Johnson, PhD, Leslie Andritsos, MD, Kristie A. Blum, MD, Jeffrey A. Jones, MD, MPH, Elizabeth A. Wiley, Weihong Hu, Joshua Hessler, Lisa L. Smith, David M. Lucas, PhD, Karen Small, Paul Statkevich, Michael R. Grever, MD, Rajat Bannerji, MD, PhD, John C. Byrd, MD

Blood (2009) 114 (22): 886.

https://doi.org/10.1182/blood.V114.22.886.886

Published: 2009

Journal Articles

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

Blood (2008) 112 (13): 5180–5189.

https://doi.org/10.1182/blood-2008-01-133108

Published: 2008

Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3104.

https://doi.org/10.1182/blood.V110.11.3104.3104

Published: 2007

Journal Articles

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Nyla A. Heerema, PhD, John C. Byrd, MD, Leslie A. Andritsos, MD, Gerard Lozanski, MD, Kristie Blum, MD, Beth Fischer, RN, Jeffrey A. Jones, MD, Mollie E. Moran, CNP, Sarah Groering, Larry J. Schaaf, Linda S. Mahoney, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch A. Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Thomas S. Lin, MD

Blood (2007) 110 (11): 3107.

https://doi.org/10.1182/blood.V110.11.3107.3107

Published: 2007

Journal Articles

Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.

Leslie A. Andritsos, MD, Amy J. Johnson, Ph.D., William Blum, M.D., Cheryl Kefauver, R.N., Farrukh Awan, M.D., Lisa L. Smith, Rosa Lapalombella, Da-Sheng Wang, Robert D. Knight, Ching-Shih Chen, Ph.D., John C. Byrd, M.D.

Blood (2007) 110 (11): 4727.

https://doi.org/10.1182/blood.V110.11.4727.4727

Published: 2007

NARROW

Targeting BTK through microRNA in chronic lymphocytic leukemia

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only